Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
11 Leser
Artikel bewerten:
(0)

Leading the Way in Patient Care - Aegate Partners Address the Challenge of Falsified Medicines Directive

CAMBRIDGE, England, February 24, 2015 /PRNewswire/ --

  • Following the announcement in September of the Aegate Safe Medicine Partner Program, the network's inaugural symposium took place in Amsterdam
  • Aegate announces geographic expansion for the AegatePROTECT' services for European Patient Medication Safety
  • Aegate announces value add services in co-operation with its Eco Partners

Farmad has 1,036 active pharmacies using Aegate services, the following quotes from pharmacists confirm the trust they have in Aegate's messaging technology:

"Taking up your responsibility as a carer to the fullest, using recent and real time pharmaceutical information that can be shared easily with your colleagues free of charge, activating an automatic update in my system."

"In a hectic pharmacy nowadays, a pharmacist is always busy thinking about everything, so that information concerning patient security, that maximises your role as a personal adviser, is a definite help from which the patient undoubtedly will feel the benefit."

A further presentation by the general manager of APB BelgianPharmaceuticalAssociation reconfirmed Aegate's credibility within the platform. The event clarified that Aegate's robust systemarchitecture and ease of integration reassures that FMD implementation is indeed care-free. Aegate and its partners are prepared to meet these challenges easily and with no disruption to pharmaceutical services.

Workshops were also held to stimulate new and innovative ideas between Aegate and its partners - plans going forward will include new services development and other forward thinking initiatives proposed by Aegate partners.

Aegate CEO Mark De Simone concluded the meeting underlining the sense of urgency to prepare for and implement FMD requirements, Aegate as your partner will ensure success meeting this challenge - an Aegate Safe pharmacy is a safer pharmacy.

About Aegate

With a documented history of some 3 billion medicines scanned to date with an average rate of 200k transactions per hour across 15k dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices in Belgium, Italy, Switzerland and the UK. Our mission is to protect patients from falsified, recalled or expired medicines.

We operate a highly secure real-time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.

For more information on Aegate, please visit http://www.aegate.com



CompanyContact:
Graham Smith
Commercial Director Aegate Ltd
Cambridge Technology Centre
Melbourn SG8 6DP UK

T: +44-1763-268160
M: +44-7785-748970


W: http://www.aegate.com

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.